report revenu street estim
on-going ep penni street estim manag lower
ep guidanc mid-point although unchang
adjust envista ipo non-control interest increas
ep estim maintain premium ep multipl share howev
comp declin price target
result report organ revenu growth
consensu life scienc revenu grew organ
street estim diagnost grew organ
consensu environment grew cc
street estim due lower product id revenu dental revenu decreas
organ street estim gross margin improv
yoy oper margin declin yoy on-going
ep street estim
busi updat dd growth beckman coulter ls hsd pall msd
leica molecular devic european soft sciex lead
yoy declin tough comp manag expect sciex bounc back
recogn pull forward pall leica biosystem radiomet
cepheid grew dd beckman coulter dx msd particularli impress
consist msd growth beckman dx consid on-going competit
launch trojan dd msd chemtreat lsd hach declin
product id videojet msd esko/x-rit lsd although due part
difficult yoy comp almost ly china grew hsd brexit impact
outlook manag establish core revenu growth target
increas core growth target
chang impli bpt increas adjust non-cor dental
asset upon first glanc non-gaap ep street
estim howev consid drag envista nci
ep guidanc essenti unchang
stock anoth good quarter net updat ep
guidanc howev although believ top line guidanc conserv
maintain premium ep multipl group peg price target
ep estim
accordingli recogn consist perform maintain current rate
competit regul reimburs acquisit integr
conglomer focus healthcar environment product
ep
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
million except share per share data
updat
net incom common
good sold
good sold
good sold
current disclosur inform compani locat
